EX-99.2O 3 a1q20128-kexhibit992o.htm FINANCIALS 1Q20128-KExhibit992O

Exhibit 99.2O




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
FIRST QUARTER
 
 
 
 
 
 
 
 
 
 
 
2012
 
2011
 
Percent

 
 
 
Percent

 
 
 
Percent

 
Increase

 
Amount

 
to Sales

 
Amount

 
to Sales

 
(Decrease)

Sales to customers
$
16,139

 
100.0

 
$
16,173

 
100.0

 
(0.2
)
Cost of products sold
4,915

 
30.4

 
4,778

 
29.5

 
2.9

Selling, marketing and administrative expenses
5,015

 
31.1

 
5,056

 
31.3

 
(0.8
)
Research and development expense
1,645

 
10.2

 
1,738

 
10.8

 
(5.4
)
Interest (income)expense, net
130

 
0.8

 
104

 
0.6

 
25.0

Other (income)expense, net
(611
)
 
(3.8
)
 
(13
)
 
(0.1
)
 
 
Earnings before provision for taxes on income
5,045

 
31.3

 
4,510

 
27.9

 
11.9

Provision for taxes on income
1,135

 
7.1

 
1,034

 
6.4

 
9.8

Net earnings
$
3,910

 
24.2

 
$
3,476

 
21.5

 
12.5

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
$
1.41

 
 
 
$
1.25

 
 
 
12.8

 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,774.9

 
 
 
2,772.7

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
22.5

%
 
 
22.9

%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
     Earnings before provision for taxes on income
$
4,928

 
30.5

 
$
4,856

 
30.0

 
1.5

     Net earnings
$
3,804

 
23.6

 
$
3,747

 
23.2

 
1.5

     Net earnings per share (Diluted)
$
1.37

 
 
 
$
1.35

 
 
 
1.5

     Effective tax rate
22.8

%
 
 
22.8

%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 (A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. 










Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Quarter
 
% Incr. /
 
(Dollars in Millions Except Per Share Data)
2012
 
2011
 
(Decr.)
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
$
5,045

 
4,510

 
11.9

%
 
 
 
 
 
 
 
Litigation/DePuy ASR™ Hip related costs
—

 
346

 
 
 
 
 
 
 
 
 
 
Currency related and costs associated with planned acquisition of Synthes, Inc.
(117
)
 
—

 
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as adjusted
$
4,928

 
4,856

 
1.5

%
 
 
 
 
 
 
 
Net Earnings - as reported
$
3,910

 
3,476

 
12.5

%
 
 
 
 
 
 
 
Litigation/DePuy ASR™ Hip related costs
—

 
271

 
 
 
 
 
 
 
 
 
 
Currency related and costs associated with planned acquisition of Synthes, Inc.
(106
)
 
—

 
 
 
 
 
 
 
 
 
 
Net Earnings - as adjusted
$
3,804

 
3,747

 
1.5

%
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
$
1.41

 
1.25

 
12.8

%
 
 
 
 
 
 
 
Litigation/DePuy ASR™ Hip related costs
—

 
0.10

 
 
 
 
 
 
 
 
 
 
Currency related and costs associated with planned acquisition of Synthes, Inc.
(0.04
)
 
—

 
 
 
 
 
 
 
 
 
 
Diluted Net Earnings per share - as adjusted
$
1.37

 
1.35

 
1.5

%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for
taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.







Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FIRST QUARTER
 
 
 
 
 
Percent Change
 
2012
 
2011
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
$
1,316

 
1,345

 
(2.2
)
%
(2.2
)
 
—

    International
2,279

 
2,337

 
(2.5
)
 
0.4

 
(2.9
)
 
3,595

 
3,682

 
(2.4
)
 
(0.6
)
 
(1.8
)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
3,026

 
3,391

 
(10.8
)
 
(10.8
)
 
—

    International
3,107

 
2,668

 
16.5

 
19.6

 
(3.1
)
 
6,133

 
6,059

 
1.2

 
2.6

 
(1.4
)
 
 
 
 
 
 
 
 
 
 
Med Devices & Diagnostics
 
 
 
 
 
 
 
 
 
    U.S.
2,877

 
2,872

 
0.2

 
0.2

 
—

    International
3,534

 
3,560

 
(0.7
)
 
0.7

 
(1.4
)
 
6,411

 
6,432

 
(0.3
)
 
0.5

 
(0.8
)
 
 
 
 
 
 
 
 
 
 
U.S.
7,219

 
7,608

 
(5.1
)
 
(5.1
)
 
—

International
8,920

 
8,565

 
4.1

 
6.4

 
(2.3
)
Worldwide
$
16,139

 
16,173

 
(0.2
)
%
1.0

 
(1.2
)









Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FIRST QUARTER
 
 
 
 
 
Percent Change
 
2012
 
2011
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
$
7,219

 
7,608

 
(5.1
)
%
(5.1
)
 
—

 
 
 
 
 
 
 
 
 
 
Europe
4,194

 
4,183

 
0.3

 
4.5

 
(4.2
)
Western Hemisphere excluding U.S.
1,714

 
1,436

 
19.4

 
23.3

 
(3.9
)
Asia-Pacific, Africa
3,012

 
2,946

 
2.2

 
1.2

 
1.0

International
8,920

 
8,565

 
4.1

 
6.4

 
(2.3
)
 
 
 
 
 
 
 
 
 
 
Worldwide
$
16,139

 
16,173

 
(0.2
)
%
1.0

 
(1.2
)









Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2012
 
2011
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
99

 
105

 
(5.7
)%
(5.7
)%
—
 %
Intl
 
 
441

 
456

 
(3.3
)
(0.4
)
(2.9
)
WW
 
 
540

 
561

 
(3.7
)
(1.4
)
(2.3
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
155

 
163

 
(4.9
)
(4.9
)
—

Intl
 
 
232

 
228

 
1.8

4.7

(2.9
)
WW
 
 
387

 
391

 
(1.0
)
0.7

(1.7
)
 
 
 
 
 
 
 
 
 
 
OTC/NUTRITIONALS
 
 
 
 
 
 
 
 
 
US
 
 
381

 
397

 
(4.0
)
(4.0
)
—

Intl
 
 
723

 
732

 
(1.2
)
1.7

(2.9
)
WW
 
 
1,104

 
1,129

 
(2.2
)
(0.3
)
(1.9
)
 
 
 
 
 
 
 
 
 
 
SKIN CARE
 
 
 
 
 
 
 
 
 
US
 
 
453

 
426

 
6.3

6.3

—

Intl
 
 
454

 
473

 
(4.0
)
(1.7
)
(2.3
)
WW
 
 
907

 
899

 
0.9

2.1

(1.2
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
93

 
125

 
(25.6
)
(25.6
)
—

Intl
 
 
316

 
334

 
(5.4
)
(1.7
)
(3.7
)
WW
 
 
409

 
459

 
(10.9
)
(8.2
)
(2.7
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE/OTHER
 
 
 
 
 
 
 
 
 
US
 
 
135

 
129

 
4.7

4.7

—

Intl
 
 
113

 
114

 
(0.9
)
1.7

(2.6
)
WW
 
 
248

 
243

 
2.1

3.3

(1.2
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
1,316

 
1,345

 
(2.2
)
(2.2
)
—

Intl
 
 
2,279

 
2,337

 
(2.5
)
0.4

(2.9
)
WW
 
$
3,595

 
3,682

 
(2.4
)%
(0.6
)%
(1.8
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2012
 
2011
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
1,453

 
1,436

 
1.2
 %
1.2
 %
—
 %
Intl
 
 
442

 
144

 
*

*

(2.2
)
WW
 
 
1,895

 
1,580

 
19.9

20.5

(0.6
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
882

 
788

 
11.9

11.9

—

     US Exports (3)
 
 
378

 
490

 
(22.9
)
(22.9
)
—

     Intl
 
 
261

 
7

 
*

*

(2.2
)
     WW
 
 
1,521

 
1,285

 
18.4

18.4

0.0

     SIMPONI
 
 
 
 
 
 
 
 
 
     US
 
 
64

 
53

 
20.8

20.8

—

     Intl
 
 
52

 
42

 
23.8

25.0

(1.2
)
     WW
 
 
116

 
95

 
22.1

22.6

(0.5
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
129

 
105

 
22.9

22.9

—

     Intl
 
 
92

 
61

 
50.8

53.9

(3.1
)
     WW
 
 
221

 
166

 
33.1

34.8

(1.7
)
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
37

 
34

 
8.8

10.7

(1.9
)
     WW
 
 
37

 
34

 
8.8

10.7

(1.9
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
242

 
624

 
(61.2
)
(61.2
)
—

Intl
 
 
513

 
307

 
67.1

70.5

(3.4
)
WW
 
 
755

 
931

 
(18.9
)
(17.0
)
(1.9
)
     INTELENCE
 
 
 
 
 
 
 
 
 
     US
 
 
43

 
38

 
13.2

13.2

—

     Intl
 
 
37

 
31

 
19.4

23.0

(3.6
)
     WW
 
 
80

 
69

 
15.9

17.8

(1.9
)
     LEVAQUIN/FLOXIN
 
 
 
 
 
 
 
 
 
     US
 
 
18

 
422

 
(95.7
)
(95.7
)
—

     Intl
 
 
11

 
12

 
(8.3
)
(4.8
)
(3.5
)
     WW
 
 
29

 
434

 
(93.3
)
(93.2
)
(0.1
)
     PREZISTA
 
 
 
 
 
 
 
 
 
     US
 
 
160

 
126

 
27.0

27.0

—

     Intl
 
 
164

 
140

 
17.1

20.9

(3.8
)
     WW
 
 
324

 
266

 
21.8

24.1

(2.3
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
21

 
38

 
(44.7
)
(44.7
)
—

     Intl
 
 
301

 
124

 
*

*

(3.2
)
     WW
 
 
322

 
162

 
98.8

*

(3.0
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2012
 
2011
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
674

 
688

 
(2.0
)%
(2.0
)%
—
 %
Intl
 
 
973

 
1,057

 
(7.9
)
(5.8
)
(2.1
)
WW
 
 
1,647

 
1,745

 
(5.6
)
(4.3
)
(1.3
)
     CONCERTA/METHYLPHENIDATE
 
 
 
 
 
 
 
 
 
     US
 
 
197

 
254

 
(22.4
)
(22.4
)
—

     Intl
 
 
111

 
108

 
2.8

5.8

(3.0
)
     WW
 
 
308

 
362

 
(14.9
)
(14.0
)
(0.9
)
     INVEGA
 
 
 
 
 
 
 
 
 
     US
 
 
69

 
69

 
0.0

0.0

—

     Intl
 
 
52

 
51

 
2.0

3.7

(1.7
)
     WW
 
 
121

 
120

 
0.8

1.5

(0.7
)
     INVEGA SUSTENNA
 
 
 
 
 
 
 
 
 
     US
 
 
100

 
65

 
53.8

53.8

—

     Intl
 
 
61

 
—

 
*

*

—

     WW
 
 
161

 
65

 
*

*

—

     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
113

 
114

 
(0.9
)
(0.9
)
—

     Intl
 
 
248

 
290

 
(14.5
)
(11.8
)
(2.7
)
     WW
 
 
361

 
404

 
(10.6
)
(8.7
)
(1.9
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
195

 
186

 
4.8

4.8

—

     Intl
 
 
501

 
608

 
(17.6
)
(16.2
)
(1.4
)
     WW
 
 
696

 
794

 
(12.3
)
(11.2
)
(1.1
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
107

 
64

 
67.2

67.2

—

Intl
 
 
489

 
375

 
30.4

33.7

(3.3
)
WW
 
 
596

 
439

 
35.8

38.5

(2.7
)
     DOXIL/CAELYX
 
 
 
 
 
 
 
 
 
     US
 
 
7

 
64

 
(89.1
)
(89.1
)
—

     Intl
 
 
17

 
75

 
(77.3
)
(76.2
)
(1.1
)
     WW
 
 
24

 
139

 
(82.7
)
(82.1
)
(0.6
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
353

 
280

 
26.1

29.3

(3.2
)
     WW
 
 
353

 
280

 
26.1

29.3

(3.2
)
     ZYTIGA
 
 
 
 
 
 
 
 
 
     US
 
 
100

 
—

 
*

*

—

     Intl
 
 
100

 
5

 
*

*

(1.9
)
     WW
 
 
200

 
5

 
*

*

(1.9
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
19

 
15

 
26.7

29.7

(3.0
)
     WW
 
 
19

 
15

 
26.7

29.7

(3.0
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2012
 
2011
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL OTHER
 
 
 
 
 
 
 
 
 
US
 
$
550
 
579
 
(5.0
)%
(5.0
)%
—
 %
Intl
 
 
690
 
785
 
(12.1
)
(10.0
)
(2.1
)
WW
 
 
1,240
 
1,364
 
(9.1
)
(7.9
)
(1.2
)
     ACIPHEX/PARIET
 
 
 
 
 
 
 
 
 
     US
 
 
96
 
109
 
(11.9
)
(11.9
)
—

     Intl
 
 
126
 
130
 
(3.1
)
—

(3.1
)
     WW
 
 
222
 
239
 
(7.1
)
(5.4
)
(1.7
)
     PROCRIT/EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
204
 
190
 
7.4

7.4

—

     Intl
 
 
172
 
207
 
(16.9
)
(14.0
)
(2.9
)
     WW
 
 
376
 
397
 
(5.3
)
(3.8
)
(1.5
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
250
 
280
 
(10.7
)
(10.7
)
—

     Intl
 
 
392
 
448
 
(12.5
)
(11.1
)
(1.4
)
     WW
 
 
642
 
728
 
(11.8
)
(11.0
)
(0.8
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
3,026
 
3,391
 
(10.8
)
(10.8
)
—

Intl
 
 
3,107
 
2,668
 
16.5

19.6

(3.1
)
WW
 
$
6,133
 
6,059
 
1.2
 %
2.6
 %
(1.4
)%
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2012
 
2011
 
Reported
Operational (1)
Currency

MEDICAL DEVICES AND DIAGNOSTICS (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR CARE
 
 
 
 
 
 
US
 
$
176

 
242

 
(27.3
)%
(27.3
)%
—
 %
Intl
 
 
306

 
393

 
(22.1
)
(21.2
)
(0.9
)
WW
 
 
482

 
635

 
(24.1
)
(23.5
)
(0.6
)
 
 
 
 
 
 
 
 
 
 
DIABETES CARE
 
 
 
 
 
 
 
 
 
US
 
 
352

 
311

 
13.2

13.2

—

Intl
 
 
318

 
326

 
(2.5
)
0.2

(2.7
)
WW
 
 
670

 
637

 
5.2

6.6

(1.4
)
 
 
 
 
 
 
 
 
 
 
DIAGNOSTICS
 
 
 
 
 
 
 
 
 
US
 
 
253

 
265

 
(4.5
)
(4.5
)
—

Intl
 
 
259

 
256

 
1.2

2.5

(1.3
)
WW
 
 
512

 
521

 
(1.7
)
(1.1
)
(0.6
)
 
 
 
 
 
 
 
 
 
 
GENERAL SURGERY
 
 
 
 
 
 
 
 
 
US
 
 
593

 
596

 
(0.5
)
(0.5
)
—

Intl
 
 
1,032

 
1,025

 
0.7

2.6

(1.9
)
WW
 
 
1,625

 
1,621

 
0.2

1.4

(1.2
)
 
 
 
 
 
 
 
 
 
 
INFECTION PREVENTION/OTHER
 
 
 
 
 
 
 
 
 
US
 
 
116

 
95

 
22.1

22.1

—

Intl
 
 
128

 
121

 
5.8

6.5

(0.7
)
WW
 
 
244

 
216

 
13.0

13.4

(0.4
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
US
 
 
783

 
811

 
(3.5
)
(3.5
)
—

Intl
 
 
710

 
692

 
2.6

4.1

(1.5
)
WW
 
 
1,493

 
1,503

 
(0.7
)
0.0

(0.7
)
 
 
 
 
 
 
 
 
 
 
SPECIALTY SURGERY
 
 
 
 
 
 
 
 
 
US
 
 
327

 
296

 
10.5

10.5

—

Intl
 
 
301

 
281

 
7.1

9.3

(2.2
)
WW
 
 
628

 
577

 
8.8

9.9

(1.1
)
 
 
 
 
 
 
 
 
 
 
VISION CARE
 
 
 
 
 
 
 
 
 
US
 
 
277

 
256

 
8.2

8.2

—

Intl
 
 
480

 
466

 
3.0

2.6

0.4

WW
 
 
757

 
722

 
4.8

4.5

0.3

 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
 
 
US
 
 
2,877

 
2,872

 
0.2

0.2

—

Intl
 
 
3,534

 
3,560

 
(0.7
)
0.7

(1.4
)
WW
 
$
6,411

 
6,432

 
(0.3
)%
0.5
 %
(0.8
)%
*Percentage greater than 100%
 
 
 
 
 
 
 
 
 
(1) Operational growth excludes the effect of currency
 
 
 
 
 
 
(2) Select areas (unaudited)
 
 
 
 
 
 
 
 
 
(3) Reported as U.S. sales
 
 
 
 
 
 
 
 
 
(4) Prior year amounts have been reclassified to conform to current year product disclosure